Implication of enhanced recovery after surgery in the surgical management of hypopharyngeal squamous cell carcinoma.
10.3760/cma.j.cn115330-20200507-00385
- Author:
Sheng Da CAO
1
;
Wen Ming LI
1
;
Dong Min WEI
1
;
Ye QIAN
1
;
Hua JIANG
1
;
Yue Dong HOU
2
;
Da Peng LEI
1
;
Xin Liang PAN
1
Author Information
1. Department of Otorhinolaryngology, Qilu Hospital of Shandong University, National Health Commission Key Laboratory of Otorhinolaryngology (Shandong University), Jinan 250012, China.
2. Department of Anesthesia, Qilu Hospital of Shandong University, Jinan 250012, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Enhanced Recovery After Surgery;
Female;
Head and Neck Neoplasms;
Humans;
Length of Stay;
Male;
Middle Aged;
Postoperative Complications/epidemiology*;
Retrospective Studies;
Squamous Cell Carcinoma of Head and Neck;
Treatment Outcome
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2021;56(3):216-220
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the safety and efficacy of enhanced recovery after surgery (ERAS) in the clinical management of hypopharyngeal squamous cell carcinoma (HSCC). Methods: In this retrospective study, a total of 168 patients with pyriform sinus carcinoma in Qilu Hospital of Shandong University from January 2015 to January 2019 were divided into two groups, based on the different perioperative interventions that patients received, i.e. the ERAS group (n=64) and the conventional group (n=104), including 164 males and 4 females, whose ages ranged from 42 to 84 years old. The difference between two groups in the operative time, postoperative nutritional status, incidences of postoperative complications and postoperative hospitalization time were compared using the student's t test, Chi-squared test or Fisher's exact test. Results: Compared with the conventional group, patients in the ERAS group had significantly shorter operative time [(166.8±58.2) min vs. (183.3±39.9) min,t=-2.72, P=0.031], higher levels of postoperative serum albumin [(38.3±4.2) μmol/L vs. (36.6±3.3) μmol/L, t=2.73, P=0.007] and more body weight [(65.4±9.4) kg vs. (62.1±9.4) kg, t=2.22, P=0.028], lower incidences of postoperative subcutaneous infection [7.8% (5/64) vs. 20.2% (21/104), χ²=4.64, P=0.03] and severe pneumonia [4.7% (3/64) vs. 15.4% (16/104), χ²=4.52, P=0.03], and shorter postoperative hospitalization time [(16.5±3.9) d vs. (18.2±4.3) d, t=-2.65, P<0.05]. Conclusion: ERAS is effective and safe in the surgical management of HSCC, with benefits in reducing the operative stress via saving operation time, shortening the hospitalization time, ameliorating nutritional status and decreasing the incidences of complications.
